RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Britain Courts Anthropic Amid US Defense Department Dispute 
Apple Turns 50: From Garage Startup to AI Crossroads 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
 & Lead Plaintiff Deadline: January 9, 2017 - EconoTimes)
NEW YORK, Dec. 06, 2016 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against ProNAi Therapeutics, Inc. (“ProNAi” or the “Company”) (NASDAQ:DNAI) and certain of its officers, and is on behalf of shareholders who purchased or otherwise acquired ProNAi securities between July 15, 2015 and June 6, 2016, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/dnai.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements about the potential and effectiveness of its drug product candidate PNT2258 in its public filings, causing ProNAi’s stock to be falsely inflated throughout the Class Period.
On June 6, 2016, ProNAi released its interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Nick Glover, President and CEO said, “Although [PNT2258] observed modest efficacy …in [the] interim analysis of Wolverine,” the Company has “decided to suspend the development of PNT2258” because the results were not “robust enough to justify continued development of the drug in DLBCL.” Following this news, ProNAi stock dropped from a previous market close on June 3 of $6.38 per share to close at just $2.07 per share on June 6, 2016.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/dnai or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in ProNAi you have until January 9, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
